Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 07
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Korro Bio Inc
KRRO
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$9.76
-0.21
-2.11%
Últ. Act.: Oct 6, 4:00 PM
$9.76
-0.21
-2.11%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Korro Bio Financials
Korro Bio (KRRO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the
Benzinga Newsdesk
PRO
Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49) per share from the
Benzinga Newsdesk
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.
Vandana Singh
PRO
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the
Benzinga Newsdesk
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
Avi Kapoor
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results
Avi Kapoor
